Cryoport Q3 2026 Revenue Growth Accelerates, Guidance Raised, But Profitability Still Unproven

What happened

Cryoport reported Q3 2026 revenue of $50.2 million, a 14% year-over-year increase, with commercial cell and gene therapy revenue up 20%. The company now supports a record 788 global clinical trials and 23 commercially approved therapies, up from 745 and 19, respectively, a year earlier. Management raised full-year 2026 revenue guidance to $197-199 million, implying continued growth in the fourth quarter. However, the press release did not include profitability or cash flow figures, and prior filings showed structural losses, negative EBITDA, and negative interest coverage. These results suggest strengthening CGT momentum but do not yet confirm a path to durable profitability.

Implication

Cryoport's accelerating growth and raised guidance indicate strengthening demand for its integrated CGT supply chain services, but the company has yet to demonstrate positive EBITDA or free cash flow. The balance sheet remains a source of resilience with over $400 million in cash and short-term investments, providing time to scale operations without immediate dilution risk. Investors should monitor whether the higher revenue translates into improved operating leverage and margin expansion, as previous cost structures have kept the company loss-making. The growing number of supported therapies and trials could lead to higher-margin commercial revenue over time, but competition from larger logistics players and execution risks around recent partnerships remain concerns. Until Cryoport shows consecutive quarters of narrowing losses and eventual breakeven, the stock is best viewed as a speculative holding rather than a value investment.

Thesis delta

The thesis improves marginally as Cryoport posts stronger-than-expected growth in commercial CGT revenue and expands its supported pipeline, suggesting the company is gaining traction in a high-value niche. However, without updated profitability metrics, the core concern of structural losses and negative cash flow remains unaddressed. Consequently, the prior WAIT stance becomes a more vigilant WAIT, with an upgrade to POTENTIAL BUY contingent on evidence of sustained positive EBITDA and free cash flow.